HK1210025A1 - Method and agent for the treatment and prophylaxis of diseases caused by ()rna-containing viruses ()rna - Google Patents

Method and agent for the treatment and prophylaxis of diseases caused by ()rna-containing viruses ()rna

Info

Publication number
HK1210025A1
HK1210025A1 HK15110781.5A HK15110781A HK1210025A1 HK 1210025 A1 HK1210025 A1 HK 1210025A1 HK 15110781 A HK15110781 A HK 15110781A HK 1210025 A1 HK1210025 A1 HK 1210025A1
Authority
HK
Hong Kong
Prior art keywords
rna
prophylaxis
agent
treatment
diseases caused
Prior art date
Application number
HK15110781.5A
Other languages
English (en)
Chinese (zh)
Inventor
弗拉迪米爾．葉夫根尼耶維奇．涅博利辛
謝爾蓋．弗拉基米羅維奇．鮑里謝維奇
安德烈．尤里耶維奇．葉戈羅夫
Original Assignee
Obschestvo S Ogranichennoi Otvetstvennostiyu Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obschestvo S Ogranichennoi Otvetstvennostiyu Pharm filed Critical Obschestvo S Ogranichennoi Otvetstvennostiyu Pharm
Publication of HK1210025A1 publication Critical patent/HK1210025A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15110781.5A 2012-08-30 2015-11-02 Method and agent for the treatment and prophylaxis of diseases caused by ()rna-containing viruses ()rna HK1210025A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2012137097/15A RU2518314C2 (ru) 2012-08-30 2012-08-30 Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами
PCT/RU2013/000751 WO2014035297A1 (ru) 2012-08-30 2013-08-29 Способ и средство для лечения и профилактики заболеваний, вызываемых (+) рнк-содержащими вирусами

Publications (1)

Publication Number Publication Date
HK1210025A1 true HK1210025A1 (en) 2016-04-15

Family

ID=50183972

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110781.5A HK1210025A1 (en) 2012-08-30 2015-11-02 Method and agent for the treatment and prophylaxis of diseases caused by ()rna-containing viruses ()rna

Country Status (17)

Country Link
US (1) US9820970B2 (pl)
EP (1) EP2893936B1 (pl)
JP (1) JP6328638B2 (pl)
CN (1) CN104684569B (pl)
CA (1) CA2883908C (pl)
CY (1) CY1120158T1 (pl)
DK (1) DK2893936T3 (pl)
EA (1) EA028541B1 (pl)
ES (1) ES2667342T3 (pl)
HK (1) HK1210025A1 (pl)
HU (1) HUE036805T2 (pl)
LT (1) LT2893936T (pl)
PL (1) PL2893936T3 (pl)
PT (1) PT2893936T (pl)
RU (1) RU2518314C2 (pl)
SI (1) SI2893936T1 (pl)
WO (1) WO2014035297A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504673B2 (en) * 2009-05-21 2016-11-29 LTD “Valenta-Intellekt” Agent for the prophylaxis and treatment of highly pathogenic infectious diseases
RU2628800C2 (ru) * 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
RU2746692C1 (ru) * 2020-04-14 2021-04-19 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые составы 2-(имидазол-4-ил)-этанамида пентандиовой-1,5 кислоты для лечения и профилактики вирусных заболеваний
RU2744854C1 (ru) * 2020-02-11 2021-03-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Жидкая лекарственная форма для лечения и профилактики гриппа и орви
RU2770518C2 (ru) * 2020-02-11 2022-04-18 Общество С Ограниченной Ответственностью "Валента-Интеллект" Жидкая лекарственная форма для лечения и профилактики гриппа и орви
RU2770521C2 (ru) * 2020-02-11 2022-04-18 Общество С Ограниченной Ответственностью "Валента-Интеллект" Жидкая лекарственная форма для лечения и профилактики гриппа и орви
CN114984030A (zh) * 2022-06-23 2022-09-02 中国人民解放军海军军医大学 利巴韦林在制备抗蜱传脑炎病毒药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2141483C1 (ru) * 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
WO1999018993A1 (fr) * 1997-10-13 1999-04-22 Otsuka Pharmaceutical Co., Ltd. Produit d'amelioration de l'effet curatif sur l'hepatite c et son application
HUP0400624A2 (hu) 1998-04-30 2004-06-28 Agouron Pharmaceuticals, Inc. Picornavírus-ellenes vegyületek, előállításuk és alkalmazásuk
RU2191594C1 (ru) * 2001-04-03 2002-10-27 Григорян Седа Суреновна Средство и способ повышения резистентности к инфекции
ATE353658T1 (de) * 2002-06-03 2007-03-15 Nat Health Research Institutes Behandlung von flavivirusinfizierungen
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
RU2335495C2 (ru) * 2005-06-15 2008-10-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" N-ацильные производные аминокислот, их фармацевтически приемлевые соли, фармацевтическая композиция и применение в качестве гиполипидемических средств
RU2338552C2 (ru) * 2006-09-19 2008-11-20 Владимир Евгеньевич Небольсин Фармацевтическая композиция для ингаляции
US9504673B2 (en) * 2009-05-21 2016-11-29 LTD “Valenta-Intellekt” Agent for the prophylaxis and treatment of highly pathogenic infectious diseases
RU2496512C1 (ru) * 2012-03-14 2013-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способ лечения вирусного гепатита с

Also Published As

Publication number Publication date
SI2893936T1 (en) 2018-07-31
US9820970B2 (en) 2017-11-21
CN104684569A (zh) 2015-06-03
CA2883908A1 (en) 2014-03-06
CA2883908C (en) 2019-06-04
JP6328638B2 (ja) 2018-05-23
RU2012137097A (ru) 2014-03-10
PL2893936T3 (pl) 2018-09-28
EP2893936A4 (en) 2016-03-16
PT2893936T (pt) 2018-05-02
EP2893936B1 (en) 2018-04-04
ES2667342T3 (es) 2018-05-10
EA201590460A1 (ru) 2015-06-30
CY1120158T1 (el) 2018-12-12
CN104684569B (zh) 2018-03-02
WO2014035297A1 (ru) 2014-03-06
US20150209330A1 (en) 2015-07-30
EP2893936A1 (en) 2015-07-15
DK2893936T3 (en) 2018-05-28
RU2518314C2 (ru) 2014-06-10
EA028541B1 (ru) 2017-11-30
HUE036805T2 (hu) 2018-07-30
LT2893936T (lt) 2018-06-25
JP2015526513A (ja) 2015-09-10

Similar Documents

Publication Publication Date Title
HK1207636A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
HK1210463A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
EP2753618A4 (en) HETEROCYCLE-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES
HUE041553T2 (hu) Lizoszomális tárolási betegségek (LSD) kezelése és génterápia
ZA201308746B (en) Quinazoline derivatives for the treatment of viral infections and further diseases
HK1210025A1 (en) Method and agent for the treatment and prophylaxis of diseases caused by ()rna-containing viruses ()rna
EP2736528A4 (en) COMPOSITIONS AND METHODS OF TREATING HIV
HK1210022A1 (en) Methods for the treatment of hepatitis b and hepatitis d infections
EP2753611A4 (en) SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES
DK3292875T3 (en) Compositions and methods for treating diseases
HK1215173A1 (zh) 治療金黃色葡萄球菌相關疾病的方法
EP2802353A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
EP2663327A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
ZA201501601B (en) Virus purification and formulation process
IL221399A0 (en) Compositions and methods for treating viral diseases
SG11201402899TA (en) Methods and compositions for treating viral diseases
PT2838903T (pt) Métodos e composições para tratamento de infeções virais
HK1205680A1 (en) Agent for the treatment of hepatitis c virus
HK1199617A1 (en) Compositions and methods for treating viral diseases